Click here if you are having trouble viewing this message.

September newsletter

In this newsletter:

How will the newly MHRA licenced CGT Catapult manufacturing centre support developers in the UK?
What are the implications of cost-utility analysis and budget impact methodologies? Listen to our heath economics webinar.
Find out about preclinical development of cell-based medicinal products for European markets

September has brought great news for the UK cell and gene therapy industry as NICE and NHS England made the decision to fund Novartis' Kymriah. The rapid approval of the CAR-T therapy highlights the commitment of the UK to be a global leader in the development, delivery and commercialisation of cell and gene therapies. CEO Keith Thompson's comments on the news can be read here.

CGT Catapult was delighted to announce that the Stevenage manufacturing centre has been granted new licences from the MHRA. These licences will allow the facility to produce new cell and gene therapies which will be able to progress faster to clinical trials and commercial supply. The news was also covered in the Telegraph.

We hope that you were able to join our webinar in which the CGT Catapult Health Economics and Market Access team discussed assessing value for money and affordability in the UK and the US. If you missed the webinar you can listen on demand.

Share this email on social media

News

Latest from health economics: on demand webinar and new paper published
If you missed the webinar on the implications of cost-utility analysis listen on demand. The team have also published a paper on implementing performance-based, managed entry agreements which can be accessed here.

Comparing single-use agitated and static expansion technologies
Could stirred-tank bioreactors solve immunotherapy cost and scalability challenges? This study evaluates expansion potential and compares the technology to current static and wave-agitated cultures.
Access the eBook

Centre gets green light for collaborating companies to manufacture therapies
Cell and gene therapies for use in health services around the world will be produced at the centre in Stevenage following the granting of two licences from the MHRA.
Read the press release

Preclinical development of cell-based medicinal products for European markets
This paper discusses the European regulatory mechanisms open to developers to aid successful product development.
Read the paper

Meet the team at:

3-5 October 2018, La Jolla, CA
Cell and Gene Meeting on the Mesa
Join CGT Catapult CEO Keith Thompson and explore the opportunities and challenges in rare diseases along with an expert panel of speakers. The discussion will cover technical challenges, licensing, adoption and reimbursement. More information.

A number of members of the CGT Catapult Business Development team will also be in attendance, if you would like to meet with them please get in touch.

16-19 October 2018, Lausanne, Switzerland
ESGCT Congress 2018
The team will attend and present an abstract submitted by our Industrialisation team.
More information

25-26 October 2018, London, UK
4th Annual Oxford Global Cell Series 2018
Join Dr Ricardo Baptista, Lead Process Development Scientist covering cost-effectiveness in cell and gene therapy manufacture and Dr Panos Kefalas, Head of Health Economics and Market Access discussing innovative pricing schemes for ATMPs.
More information

+44 (0) 203 728 9500
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT

The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our privacy policy. If you no longer want to hear from us unsubscribe here.